U.S. markets closed
  • S&P 500

    3,825.33
    +39.95 (+1.06%)
     
  • Dow 30

    31,097.26
    +321.86 (+1.05%)
     
  • Nasdaq

    11,127.84
    +99.14 (+0.90%)
     
  • Russell 2000

    1,727.76
    +19.77 (+1.16%)
     
  • Crude Oil

    108.80
    +0.37 (+0.34%)
     
  • Gold

    1,811.90
    +10.40 (+0.58%)
     
  • Silver

    19.78
    +0.11 (+0.57%)
     
  • EUR/USD

    1.0426
    0.0000 (-0.00%)
     
  • 10-Yr Bond

    2.8890
    0.0000 (0.00%)
     
  • GBP/USD

    1.2095
    -0.0008 (-0.06%)
     
  • USD/JPY

    135.4220
    +0.2470 (+0.18%)
     
  • BTC-USD

    19,159.38
    +57.49 (+0.30%)
     
  • CMC Crypto 200

    413.60
    -6.54 (-1.56%)
     
  • FTSE 100

    7,168.65
    -0.63 (-0.01%)
     
  • Nikkei 225

    26,153.81
    +218.19 (+0.84%)
     

Altimmune To Announce Year End 2020 Financial Results on February 25, 2021

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

GAITHERSBURG, Md., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its full year 2020 financial results on Thursday, February 25th, 2021.

Altimmune management will host a conference call for investors beginning at 8:30 am ET on Thursday, February 25th, 2021 to discuss financial results and provide a business update.

Conference Call Information:

Date:

Thursday, February 25, 2021

Time:

8:30 am Eastern Time

Domestic Dial-in:

877-423-9813

International Dial-in:

201-689-8573

Conference ID:

13716171

Webcast:

http://public.viavid.com/index.php?id=143423

About Altimmune

Altimmune is a clinical stage biopharmaceutical company focused on developing intranasal vaccines, immune modulating therapies and treatments for liver disease. Our diverse pipeline includes proprietary intranasal vaccines for COVID-19 (AdCOVID™), anthrax (NasoShield™) and influenza (NasoVAX™); an intranasal immune modulating therapeutic for COVID-19 (T-COVID™); and next generation peptide therapeutics for NASH (ALT-801) and chronic hepatitis B (HepTcell™). For more information on Altimmune, please visit www.altimmune.com.

Investor & Media Contacts:

Will Brown

Stacey Jurchison

Chief Financial Officer

Sr. Dir, Investor Relations

Phone: 240-654-1450

Phone : 410-474-8200

wbrown@altimmune.com

sjurchison@altimmune.com